Amanote Research
Register
Sign In
Real World Data (Rwd) at T=4 in the Netherlands
Value in Health
- United Kingdom
doi 10.1016/j.jval.2014.08.1042
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
November 1, 2014
Authors
X. Lie
T. Nijhuis
Publisher
Elsevier BV
Related search
Bevacizumab for Breast Cancer: Scientific Evidence Versus Real World Data (RWD) in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Report on the Current Status of the Use of Real‐world Data (RWD) and Real‐world Evidence (RWE) in Drug Development and Regulation
British Journal of Clinical Pharmacology
Pharmacology
P1.15-03 Clinical Characteristics of Long-Term Survivors With Nivolumab in Pretreated Advanced NSCLC From Real-World Data (RWD)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data
PLoS ONE
Multidisciplinary
Quasi-Experimental Methods for Real World Data
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Time to Really Share Real-World Data?
F1000Research
Genetics
Molecular Biology
Pharmacology
Biochemistry
Microbiology
Immunology
Medicine
Toxicology
Pharmaceutics
Real World Data and the Art of Maintenance Therapy
British Journal of Haematology
Hematology
Real World Data en La Sanidad Española
KnE Engineering
Prm18 - Real-World Data (Rwd) Collection Alongside Early Access to Medicines Schemes (Eams) - Nivolumab in Gastric or Gastroesophageal Junction Adenocarcinoma (Gc/Gej) After Two or More Prior Therapies
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
